Novartis shares fell up to 10% after its drug del-desiran failed to meet the primary endpoint in the Phase 3 HARBOR study for myotonic dystrophy type 1, showing no significant improvement over placebo. This setback follows another recent late-stage trial failure by Novartis with its cardiovascular drug pelacarsen. The company is reviewing the full trial data and will consult health authorities to decide the next steps for del-desiran. The failure also negatively impacted shares of other companies developing treatments for the same condition, such as Dyne Therapeutics and Sarepta Therapeutics.
Novartis shares fell sharply following the failure of its late-stage drug candidates pelacarsen and del-desiran in phase 3 trials, which impacts the company’s near-term growth prospects. Despite these setbacks, Novartis reaffirmed its revenue growth ...
Novartis announced that its drug pelacarsen, designed to lower the harmful cholesterol Lp(a), failed to significantly reduce cardiovascular events in a late-stage trial. This setback raises doubts about the effectiveness of targeting Lp(a) to prevent...
RBC Capital Markets reaffirmed its 'outperform' rating on Oxford BioMedica, despite clinical trial pauses by partners Novartis and BMS. The broker views the trial halts as having limited financial impact, with only £10-16 million in annual clinical r...
